Department of Neurology, Zhengzhou University People's Hospital, Zhengzhou, China; Department of Neurology, Henan Provincial People's Hospital, Zhengzhou, China.
Department of Neurology, Zhengzhou University People's Hospital, Zhengzhou, China; Department of Neurology, Henan Provincial People's Hospital, Zhengzhou, China; Department of Neurology, Henan University People's Hospital, Zhengzhou, China.
Neurosci Lett. 2021 Jan 10;741:135480. doi: 10.1016/j.neulet.2020.135480. Epub 2020 Nov 5.
Orexin, a neuropeptide primarily secreted by neurons in the lateral hypothalamus, has been implicated in Parkinson's disease (PD). Studies on the relationship between plasma orexin-A levels and PD are rare.
This study aimed to assess levels of plasma orexin-A in the progression of PD and to evaluate the correlation between orexin-A levels and non-motor symptoms.
Enzyme-linked immunosorbent assay was used to determine plasma orexin-A levels in 117 healthy controls and 121 PD patients, including those with early (n = 68), medium (n = 40) and advanced (n = 13) stages of the disease. Evaluation of motor symptoms and non-motor symptoms in PD patients, such as sleep disorders, cognitive dysfunction, neuropsychiatric symptoms, autonomic nervous dysfunction, hyposmia and PD-related pain, were assessed by the associated scales.
Plasma orexin-A levels were significantly higher in PD patients compared to healthy controls. Orexin-A levels were elevated in early-stage and medium-stage PD compared to healthy controls, but were decreased in advanced-stage PD. Orexin-A levels were negatively correlated with the Unified Parkinson's Disease Rating Scale Part III scores, disease duration, and dopamine receptor agonist doses, and were positively correlated with the Pittsburgh Sleep Quality Index, REM-sleep Behavior Disorder Questionnaire, 14-item Hamilton Anxiety Scale, Mini-Mental State Examination, and Non-motor Symptom Scale items 22-24 scores.
We found for the first time that plasma orexin-A levels were increased in early-stage and medium-stage PD and were decreased in advanced-stage PD. Furthermore, orexin-A levels were correlated with the non-motor symptoms of insomnia, REM-sleep behavior disorder, anxiety, cognitive dysfunction, and renal dysfunction.
食欲素是一种主要由下丘脑外侧神经元分泌的神经肽，与帕金森病（PD）有关。关于血浆食欲素 A 水平与 PD 之间关系的研究很少。
本研究旨在评估 PD 进展过程中血浆食欲素 A 水平，并评估食欲素 A 水平与非运动症状之间的相关性。
采用酶联免疫吸附法测定 117 例健康对照者和 121 例 PD 患者（包括早期（n = 68）、中期（n = 40）和晚期（n = 13）患者）的血浆食欲素 A 水平。采用相关量表评估 PD 患者的运动症状和非运动症状，如睡眠障碍、认知功能障碍、神经精神症状、自主神经功能障碍、嗅觉障碍和与 PD 相关的疼痛。
PD 患者的血浆食欲素 A 水平明显高于健康对照组。与健康对照组相比，早期和中期 PD 患者的食欲素 A 水平升高，但晚期 PD 患者的食欲素 A 水平降低。食欲素 A 水平与统一帕金森病评定量表第三部分评分、病程和多巴胺受体激动剂剂量呈负相关，与匹兹堡睡眠质量指数、快速眼动睡眠行为障碍问卷、14 项汉密尔顿焦虑量表、简易精神状态检查和非运动症状量表 22-24 项评分呈正相关。
我们首次发现，早期和中期 PD 患者的血浆食欲素 A 水平升高，晚期 PD 患者的血浆食欲素 A 水平降低。此外，食欲素 A 水平与失眠、REM 睡眠行为障碍、焦虑、认知功能障碍和肾功能障碍等非运动症状相关。
